Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
Blood
; 129(16): 2233-2245, 2017 04 20.
Article
en En
| MEDLINE
| ID: mdl-28096095
ABSTRACT
Dysregulated oncogenic serine/threonine kinases play a pathological role in diverse forms of malignancies, including multiple myeloma (MM), and thus represent potential therapeutic targets. Here, we evaluated the biological and functional role of p21-activated kinase 4 (PAK4) and its potential as a new target in MM for clinical applications. PAK4 promoted MM cell growth and survival via activation of MM survival signaling pathways, including the MEK-extracellular signal-regulated kinase pathway. Furthermore, treatment with orally bioavailable PAK4 allosteric modulator (KPT-9274) significantly impacted MM cell growth and survival in a large panel of MM cell lines and primary MM cells alone and in the presence of bone marrow microenvironment. Intriguingly, we have identified FGFR3 as a novel binding partner of PAK4 and observed significant activity of KPT-9274 against t(4;14)-positive MM cells. This set of data supports PAK4 as an oncogene in myeloma and provide the rationale for the clinical evaluation of PAK4 modulator in myeloma.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Regulación Neoplásica de la Expresión Génica
/
Inhibidores de Proteínas Quinasas
/
Receptor Tipo 3 de Factor de Crecimiento de Fibroblastos
/
Quinasas p21 Activadas
/
Mieloma Múltiple
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Blood
Año:
2017
Tipo del documento:
Article
País de afiliación:
Marruecos